|
Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focusing on sulforaphane-based medicines - Presents top line pharmacokinetic data for its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. Says the study is aimed to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the company’s lead asset SFX-01, as well as investigating how sulforaphane released from the tablet engages with targets of interest. Says SFX-01 shows no serious adverse effects and the study is on schedule for full reporting in the second quarter. Evgen Pharma says sulforaphane was released by the enteric coated tablet beyond the acid environment of the stomach as predicted, and the levels of sulforaphane and its active metabolites in blood increased predictably with increasing doses. Notes that the total levels of sulforaphane and active metabolites in blood were in the range previously seen to be effective in pre-clinical experiments and clinical studies in a range of target diseases, including breast cancer and glioblastoma. Chief Executive Officer Huw Jones says: ‘These top line results confirm release of the active ingredient from SFX-01 to the bloodstream in a time course that shows our new enteric coated tablet works as predicted. We have also seen a marked increase in blood levels with increasing dose with no serious adverse events.’ Current stock price: 4.03 pence each, up 4.7% on Wednesday around midday in London 12-month change: up 17% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
